Caris & Co Upgrades Illumina (ILMN) to Above Average
More News related to ILMN
- Illumina (ILMN) Approves New $100M Buyback
- Illumina Announces $100 Million Share Repurchase Program
- Illumina to Present at the Piper Jaffray "Unplugged" Health Care Conference
- Leerink Swann Maintains an 'Outperform' on Illumina (ILMN); Near-Term Negative, Long-Term Catalyst Rich
- Auriga Reiterates a 'Buy' on Illumina (ILMN); Lowers PT & Estimates
More News related to Upgrades
- After-Hours Movers 12/01: SNTS, ABCW, RAME, GAME Higher; HEB, SWS, RGNC, LTXC Lower
- Trading Radar for 12/2: Aeropostale (ARO), Synopsys (SNPS), Shanda Interactive (SNDA), Jo-Ann Stores (JAS) Report
- Unusual 11 Mid-Day Movers 12/01: BIOF, ZN, GSIT, CAGC, RDN Higher; STAA, LTON, ZOOM, OVTI Lower
- Notable ETF Movers 12/01: FXI, EWJ, GDX, BHH Up; FXY, UUP Lower
- Notable Analyst Rating Changes 12/01: FITB, BPFH, MENT, CLWR, LTD, SPWRA Upgraded; NFLX, NUVA Downgraded
Caris & Co upgrades Illumina (Nasdaq: ILMN) from Average to Above Average. Price target increased to $42.
To see more analyst ratings on ILMN Click Here.
Illumina, Inc. engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function.
Related Categories
UpgradesStocks Mentioned
+0.81Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
